From: RIMN@nnpi.com
Sent: Friday, November 08, 2002 2:56 PM
To: FDADockets@oc.fda.gov
Cc: mkramer@oc.fda.gov; MAMC@nnpi.com; MHOD@nnpi.com
Subject: Combination Products - Public Hearing /Nov 25, 2002

Dear Mark,
This is to inform you that Novo Nordisk Pharmaceuticals, Inc., in Princeton,
New Jersey plans to participate in the public hearing on FDA Regulation of
Combination Products to be held on November 25, 2002 at DoubleTree Hotel in
Rockville, Maryland.  The two participants are:

Mary Ann McElligott, Ph.D.
Senior Director
Regulatory Affairs, Diabetes and WHC
and 

Rima B. Nassar, Ph.D.
Assistant Director,
Regulatory Affaris, Diabetes and WHC

Thank you very much for your assistance, and we look forward to a successful
and productive outcome of the hearing.

Sincerely,
Rima Nassar